Silence Therapeutics plc
Silence Therapeutics plc is a biotechnology company that discovers and develops short interfering RNA (siRNA) medicines for diseases with significant unmet medical need. Its mRNAi GOLD platform designs siRNA candidates to silence specific disease-associated genes, primarily in liver cells, by harnessing the body’s RNA interference process. Its pipeline includes candidates for rare diseases such as polycythemia vera, and for cardiovascular and cardiometabolic conditions, including elevated lipoprotein(a), cholesterol disorders and obesity. Divesiran is in Phase 2 development, while zerlasiran is Phase 3 ready; other candidates are at preclinical or earlier clinical stages. Silence administers its siRNA medicines by subcutaneous injection. It develops product candidates and may collaborate with other companies on their development and commercialization. Its collaboration with AstraZeneca has covered siRNA therapeutics for cardiovascular, renal, metabolic and respiratory diseases. Silence is headquartered in London.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $SLN in the last 30 days.
See all $SLN insider activity →Merck (MRK) and Silence Therapeutics (SLN) operate in the same sector. MRK has a market cap of $362.27B, while SLN is $1.23B. Over the past year, MRK is up 58.1% and SLN is up 187.0%. MRK has more news coverage and analyst ratings. Merck KGaA plans to acquire Silence Therapeutics.
Silence Therapeutics (SLN) reported Q3 2026 financial results, including $247.7M in cash, $12.4M net loss, and reduced R&D/G&A expenses. The company announced positive Phase 2 trial results for divesiran and an agreement to be acquired by Merck KGaA, expected to close Q1 2027.
Silence Therapeutics plc (SLN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Silence Therapeutics Highlights Recent Business Achievements and Reports Third Quarter 2026 Financial Results 12 November 2026 LONDON, Silence Therapeutics plc, (Nasdaq: SLN), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, t
Over the past 7 days, AlphAI's AI scored 6 news stories mentioning SLN (Silence Therapeutics plc). Coverage has skewed bullish: 5 bullish, 0 neutral, and 1 bearish.
Recent SLN coverage spans mergers & acquisitions, financial news and earnings.
Target stock likely to rise on acquisition news.
Acquisition announcement is likely to drive the target's stock higher as investors price in a premium, while the Q3 results show improved cash position and reduced losses.
Acquisition premium expected to lift SLN share price.
The upcoming presentation could move the stock as investors price in the trial results.
Target shareholders should benefit from deal-premium expectations, while risk centers on closing conditions and any adverse regulatory/clinical developments.
AlphAI scores every news story that mentions SLN with an AI model for sentiment and relevance, and aggregates insider trades from Silence Therapeutics plc's SEC EDGAR Form 4 filings. Figures refresh continuously.
Merck (MRK) and Silence Therapeutics (SLN) operate in the same sector. MRK has a market cap of $362.27B, while SLN is $1.23B. Over the past year, MRK is up 58.1% and SLN is up 187.0%. MRK has more news coverage and analyst ratings. Merck KGaA plans to acquire Silence Therapeutics.
Silence Therapeutics (SLN) reported Q3 2026 financial results, including $247.7M in cash, $12.4M net loss, and reduced R&D/G&A expenses. The company announced positive Phase 2 trial results for divesiran and an agreement to be acquired by Merck KGaA, expected to close Q1 2027.
Silence Therapeutics plc (SLN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Silence Therapeutics Highlights Recent Business Achievements and Reports Third Quarter 2026 Financial Results 12 November 2026 LONDON, Silence Therapeutics plc, (Nasdaq: SLN), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, t
Silence Therapeutics announced an oral presentation on its SANRECO Phase 2 study of divesiran for polycythemia vera at ASH 2026. The presentation, by Marina Kremyanskaya, is scheduled for December 14, 2026. Silence Therapeutics is a clinical-stage biotech company focused on siRNA-based therapies.
In October 2026, The Pharma Letter reported 12 M&A deals, including four worth over $1 billion. Shionogi (TYO: 4507) acquired IntraBio for $2 billion. Viatris (Nasdaq: VTRS) agreed to buy Pacira BioSciences (Nasdaq: PCRX) for $1.65 billion. Ferring Pharmaceuticals agreed to pay up to $1.38 billion for Gameto. Merck KGaA (ETR: MRK) acquired Silence Therapeutics (Nasdaq: SLN) for about $1.3 billion.
Roche expanded its ADC partnership with Hansoh Pharma, with a deal potentially worth over $15B. Merck KGaA agreed to acquire Silence Therapeutics for $1.3B, gaining a rare blood cancer therapy and RNA tech. Retail sentiment on Stocktwits was neutral for Gilead and bullish for Merck KGaA, Silence Therapeutics, and others.
Merck (MRK) will acquire Silence Therapeutics (SLN) for $1.3B, or $20 per ADS, an 82% premium. Silence's Phase 3-ready siRNA therapy for polycythemia vera will join Merck's pipeline. The deal, expected to close in Q1 2027, aims to boost Merck's rare disease portfolio and aligns with its specialty healthcare strategy.
Disc Medicine's Phase 3 trial for a rare light-sensitivity disorder met all endpoints, shares rose 38.86%. Silence Therapeutics agreed to a $1.3B acquisition by Merck KGaA at a 130% premium, shares up 125.58%. Other rare blood disorder-focused companies also saw gains. Disc plans FDA resubmission by 2026 end, Silence deal expected Q1 2027.
Amazon (AMZN) rose 4.98% after Morgan Stanley raised its price target to $350, citing AWS growth. Cleveland-Cliffs (CLF) gained 16.05% on Q3 earnings beat. Disc Medicine (IRON) surged 38.86% on positive trial results. Silence Therapeutics (SLN) soared 125.58% after Merck agreed to acquire it for $1.3B. EyePoint (EYPT) plunged 85.28% on trial failure and layoffs.
Silence Therapeutics (SLN) agreed to a $1.3B all-cash takeover by Merck KGaA, representing a 130% premium. The deal focuses on Silence's RNA-based drug platform, including treatments for polycythemia vera and cardiovascular disease. The transaction is expected to close in Q1 2027, pending regulatory approval.
